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Abstract. Multiple endocrine neoplasia (MEN) syndromes are 
characterized by the association of various endocrine neopla-
sias. Prophylactic thyroidectomy is the treatment of choice for 
patients with RET gene mutations. The age at which patients 
undergo prophylactic thyroidectomy may vary depending on 
the position of the RET gene codon. In cases of MEN 2B, when 
the mutation is carried in codons 883, 918 or 922, prophylactic 
thyroidectomy is performed prior to 6 months of age, due to the 
increased aggressiveness of these heterozygosities, which are 
capable of determining the onset of medullary cancer during 
the first months of life. We present two heterozygous twin 
patients with MEN 2B syndrome who were born 32 weeks 
premature, and who underwent prophylactic thyroidectomy at 
7 months of age. The patients were carriers of the mutation at 
codon 918. We suggested the early surgery at 7 months as, due 
to their prematurity, the patients were required to gain weight 
to improve their condition prior to surgery. The two patients 
had medullary thyroid carcinoma without lymph node involve-
ment. In conclusion, for a truly prophylactic thyroidectomy, 
such patients should undergo surgery within the first month of 
life, particularly if these patients are carriers of the mutation in 
codons 883, 918 or 922.
Introduction
The endocrine abnormalities observed in multiple endocrine 
neoplasia type 2 (MEN 2) syndrome include medullary thyroid 
carcinoma, which appears in 100% of cases and pheochromo-
cytoma, which appears in 50% of cases. There are two main 
types of MEN 2: MEN 2A and 2B. There is also a familial 
form of medullary thyroid cancer. RET proto-oncogene muta-
tions are responsible for the occurrence of these syndromes. 
Patients with these mutations should undergo total thyroidec-
tomy surgery at childhood, at specific ages depending on the 
type of mutation responsible, due to the high risk of developing 
medullary thyroid carcinoma.
Case report
C.V.H., a 41-year-old carrier of MEN 2B syndrome, who 
underwent surgery for pheochromocytoma and medullary 
thyroid carcinoma, gave birth to heterozygous twins in the 
32nd week of pregnancy with a birth weight of 1000 g (M.V.V.) 
and 800 g (O.V.V.).
The patients suffered from MEN 2B, carrying the muta-
tion in codon 918, and underwent total thyroidectomy once a 
sufficient weight had been achieved (5600 and 4500 g, respec-
tively), at 7 months of age.
In both cases, the patients underwent a total thyroidectomy 
and central compartment dissection.
The postoperative course was uneventful and the patients 
were discharged from hospital within 24 h of surgery. The 
anatomopathological result of the higher birth weight sibling 
(M.V.V.) revealed the presence of medullary thyroid carcinoma 
(MTC) at a diameter of 1x2 mm in the upper pole of both 
lobes without lymph node involvement (0/14 andenopathies) 
following central compartment neck dissection. In the lower 
weight birth sibling (O.V.V.) the presence of MTC at a diameter 
of 1x1 mm was identified in the upper pole of the right lobe 
and C-cell hyperplasia in the upper pole, also without lymph 
node involvement (0/10) (Fig. 1).
Discussion
RET gene mutations are responsible for the onset of MEN 2 
syndrome. These mutations are transmitted as an autosomal 
dominant feature.
The MEN 2B subtype is responsible for approximately 
5% of cases of MEN 2. MEN 2B is characterized by an early 
development, during the first year of life, of an aggressive form 
of MTC (1).
Patients with MEN 2B who do not undergo thyroidectomy 
during the first year of life have a high risk of developing 
metastatic MTC at an early age. If prophylactic thyroidectomy 
is not performed early enough, the average life expectancy is 
21 years of age.
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The incidence of pheochromocytoma in patients with 
MEN 2B is 50%. Parathyroid adenoma or hyperplasia was not 
observed in this subtype (2).
In contrast, in 100% of these patients, it is possible to iden-
tify the presence of mucosal neuromas on the anterior dorsal 
surface of the tongue, palate, or pharynx and characteristic 
facies from childhood. All cases exhibit a marfanoid habit, 
often with scoliosis or lordosis, and hypermobility.
Prophylactic thyroidectomy is the treatment of choice for 
patients with RET gene mutations. According to the consensus 
of the Seventh International Workshop, the age for prophylactic 
thyroidectomy may vary depending on the position of the 
RET gene codon (3). In MEN 2B patients carrying the muta-
tion in codons 883, 918 or 922, prophylactic thyroidectomy 
is performed prior to 6 months of age, due to the increased 
aggressiveness of these heterozygosities (4), as they are capable 
of determining the onset of medullary cancer during the first 
months of life (5).
In the cases presented here, the patients are carriers of the 
mutation at codon 918. Therefore, early surgery was suggested. 
In both cases surgery occurred at 7 months as, due to their 
prematurity, the patients needed to gain weight to improve their 
condition prior to surgery. In any case, due to their premature 
birth, the situation was as if the patients had undergone surgery 
at 5 months of age. In both cases, despite the early intervention, 
it was not possible to perform a prophylactic thyroidectomy, 
as sites of MTC had already developed. Since surgery was not 
performed during their first month of life, as is usually the case, 
a central compartment dissection associated with thyroidec-
tomy was performed. The pathological examination of nodes 
revealed that the surgery was performed early enough, since no 
central compartment lymph node was affected.
Therefore, to make a truly prophylactic thyroidectomy, 
patients should undergo surgery within the first month of 
life, particularly if they are carriers of the mutation in codons 
883, 918 or 922. However, if the surgery is performed prior 
to the age of 6 months, it is sufficiently early that it may not 
be necessary to systematically perform central compartment 
lymphadenectomy.
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of the American Thyroid Association. Thyroid 19: 565, 2009.Figure 2. M.V.V. (left) and O.V.V. (right) at 3 months after surgery.
Figure 1. Anatomopathological result of central compartment thyroidec-
tomy and lymphadenectomy in (A) higher birth weight patient (M.V.V.) and 
(B) lower birth weight patient (O.V.V.).
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